Study Comparing Bioavailability of Oral Formulations of Vabicaserin

Completed · Phase 1

Conditions studied: Schizophrenia

In brief

The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.

Key facts

Study ID

NCT00541996

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

Starts

2007-08-01

Expected to finish

2007-10-01

Last updated by the study team

2007-12-05

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy men aged 18-50 years.

You may not qualify if…

• Any significant disease state.
• History of drug or alcohol abuse within 1 year.
• Abnormal liver function tests.

Where it is running

• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.